Section 156 of the Hatch-Waxman Act provides for restoring some of a patent’s term consumed during clinical testing and Food and Drug Administration (FDA) review of a New Drug Application (NDA) for a product covered by the patent. The extension afforded under Section 156 is of great importance to a drug manufacturer given that development of a new drug from discovery through FDA approval often takes a decade or more (10-15 years), leading to the loss of a significant portion of the term of a patent covering the drug. The dispute in Biogen International Gmbh v. Banner Life Sciences LLC, No. 2020-1373 (Fed. Cir. April 21, 2020) (Biogen v. Banner) centers around the very meaning of the term “product” as used in Section 156.
Biogen v. Banner: Patent Term Extension Inquiry Centers on ‘Active Ingredient’, Not ‘Active Moiety’
No Comments
Litigation
- Ericsson Wins Anti-Interference Injunction Against Samsung in Texas FRAND Case
- Supreme Court Will Review Doctrine of Assignor Estoppel
- Patent Filings Roundup: IP Edge End-of-Year Filing Spree, WSOU Ends Year as Top Single-Entity Filer; AC Competitors Go to War Over a Cool Million
- Alice in 2020: Slashing Software Patents and Searching for Functional Language at the Federal Circuit (Part I)
- Inventors Have Their Say on PTAB at SCOTUS in Arthrex Amicus Briefs
Recent Posts
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- From Agent to Examiner and Back Again: Practical Lessons Learned from Inside the USPTO
- Other Barks & Bites for Friday, January 15: Copyright Office Issues Final Rule on Unmatched Musical Works Under MMA, $1 Billion Copyright Verdict Against Cox Communications Upheld, USPTO Publishes Report on China IP Filings
- USPTO Report Puts Chinese Innovation Growth in Context